XML 108 R72.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaborative Arrangements and Licensing Agreements, Novartis (Details) $ in Thousands, shares in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Aug. 31, 2021 USD ($) | Mar. 31, 2017 USD ($) PerformanceObligation shares | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Jan. 31, 2023
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Revenue |  |  | $ 587,367 | $ 810,456 | $ 729,264 |
Pelacarsen API [Member] | Subsequent Event [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Percentage of royalty payments paid to Royalty Pharma on annual sales of medicine |  |  |  |  |  | 25.00%
R&D Revenue [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Revenue |  |  | 284,009 | 468,061 | $ 364,565 |
Novartis [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Maximum amount of payments receivable over term of collaboration |  |  | 900,000 |  |  |
Upfront payment received |  | $ 75,000 |  |  |  |
Maximum amount of license fees over term of collaboration |  |  | 150,000 |  |  |
Maximum amount of development milestone payments over term of collaboration |  |  | 25,000 |  |  |
Maximum amount of regulatory milestone payments over term of collaboration |  |  | 290,000 |  |  |
Maximum amount of sales milestone payments over term of collaboration |  |  | 360,000 |  |  |
Cumulative payments received |  |  | 275,000 |  |  |
Next payment to be achieved |  |  | 75,000 |  |  |
Shares issued (in shares) | shares |  | 1.6 |  |  |  |
Proceeds from sale of common stock |  | $ 100,000 |  |  |  |
Number of separate performance obligations | PerformanceObligation |  | 4 |  |  |  |
Transaction price |  | $ 108,400 |  |  |  |
Premium received on shares issued |  | 28,400 |  |  |  |
Potential premium received if common stock is purchased in the future |  | 5,000 |  |  |  |
Deferred revenue |  |  | $ 0 | $ 0 |  |
Novartis [Member] | Revenue [Member] | Strategic Partner [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Concentration percentage |  |  | 0.00% | 3.00% | 0.00% |
Novartis [Member] | R&D Services for Pelacarsen [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Transaction price |  | 64,000 |  |  |  |
Novartis [Member] | R&D Services for Olezarsen [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Transaction price |  | 40,100 |  |  |  |
Novartis [Member] | Pelacarsen API [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Royalty percentage received on sales of medicine |  |  | 20.00% |  |  |
Percentage enrollment in Lp(a) HORIZON Phase 3 cardiovascular outcome study | 50.00% |  |  |  |  |
Transaction price |  | 1,500 |  |  |  |
Revenue | $ 25,000 |  |  |  |  |
Novartis [Member] | Olezarsen API [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Transaction price |  | $ 2,800 |  |  |  |
Novartis [Member] | R&D Revenue [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Revenue |  |  | $ 200 | $ 25,500 | $ 1,000 |

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period. + References No definition available. + Details
Name: | ions_CumulativePaymentsReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of development milestone payments to be received over the term of the collaboration. + References No definition available. + Details
Name: | ions_MaximumAmountOfDevelopmentMilestonePaymentsOverTermOfCollaboration
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of license fees to be received over the term of the collaboration. + References No definition available. + Details
Name: | ions_MaximumAmountOfLicenseFeesOverTermOfCollaboration
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments the Company is eligible to receive over the term of the collaboration. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableOverTermOfCollaboration
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of regulatory milestone payments to be received over the term of the collaboration. + References No definition available. + Details
Name: | ions_MaximumAmountOfRegulatoryMilestonePaymentsOverTermOfCollaboration
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of sales milestone payments to be received over the term of the collaboration. + References No definition available. + Details
Name: | ions_MaximumAmountOfSalesMilestonePaymentsOverTermOfCollaboration
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The next payment to be achieved under the collaboration agreement. + References No definition available. + Details
Name: | ions_NextPaymentToBeAchieved
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage enrollment in the Lp(a) HORIZON Phase 3 cardiovascular outcome study of pelacarsen. + References No definition available. + Details
Name: | ions_PercentageEnrollmentInPhase3Study
Namespace Prefix: | ions_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of royalty payments paid on annual sales of medicine. + References No definition available. + Details
Name: | ions_PercentageOfRoyaltyPaymentsPaidOnAnnualSalesOfMedicine
Namespace Prefix: | ions_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The potential premium received if common stock is purchased in the future under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement. + References No definition available. + Details
Name: | ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The total amount of the premium received over the trading price of common stock at the time of purchase. + References No definition available. + Details
Name: | ions_PremiumReceivedOnSharesIssued
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the sale of common stock, including the premium paid for the purchase of common stock. + References No definition available. + Details
Name: | ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of separate performance obligations under the collaboration agreement. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty percentage received on the sales of a medicine by a collaboration partner under the collaboration agreement. + References No definition available. + Details
Name: | ions_RoyaltyPercentageReceivedOnSalesOfMedicine
Namespace Prefix: | ions_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ions_PelacarsenActivePharmaceuticalIngredientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_NovartisCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForPelacarsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForOlezarsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_OlezarsenActivePharmaceuticalIngredientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |